Hemostasis Today
NewsFeed
Headlines Hematology Health Medicine VTE ASH Plasma Donation
October, 2026
October 2026
M T W T F S S
 1234
567891011
12131415161718
19202122232425
262728293031  
Dhinesh Selvaraju: FDA Approves Narsoplimab (Yartemlea) as 1st Treatment for TA-TMA in Adults and Children
Dhinesh Selvaraju/LinkedIn
Apr 6, 2026, 16:39

Dhinesh Selvaraju: FDA Approves Narsoplimab (Yartemlea) as 1st Treatment for TA-TMA in Adults and Children

Dhinesh Selvaraju, Clinical Research Assistant at Yuva Intern by Henry Harvin, shared on LinkedIn:

”Hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA) is a life-threatening complication of allogeneic HSCT characterized by:

  • Endothelial injury and microvascular thrombosis
  • Microangiopathic hemolytic anemia
  • Consumptive thrombocytopenia
  • Progressive multi-organ dysfunction

On December 24, 2025, the U.S. Food and Drug Administration approved narsoplimab-wuug (Yartemlea; Omeros Corporation) – the first and only approved treatment for TA-TMA in adults and pediatric patients aged two years and older.

MECHANISM OF ACTION
Narsoplimab-wuug is a first-in-class human IgG4 monoclonal antibody targeting MASP-2 (Mannan-binding lectin-Associated Serine Protease-2).

How it works:

  • Selectively inhibits MASP-2, the primary effector enzyme of the lectin complement pathway
  • Blocks lectin pathway-mediated complement deposition on damaged microvascular endothelium
  • Interrupts the downstream cascade of thrombus formation, platelet consumption, and hemolysis
  • Critically preserves the classical and alternative complement pathways, maintaining essential host immune defense in immunocompromised transplant recipients

Triggers of lectin pathway activation in TA-TMA include:

  • Transplant conditioning regimens
  • Graft-versus-host disease (GVHD)
  • Calcineurin inhibitor toxicity
  • Viral infections post-transplant

CLINICAL EVIDENCE

Approval was based on a single-arm, open-label pivotal study supplemented by an expanded access program (EAP).

Pivotal Study (n = 28 adult patients):

  • TMA complete response (CR) rate: 61%
  • 100-day survival rate from TA-TMA diagnosis: 73%
  • Comparator analysis: approximately 3-fold lower mortality risk vs external historical control cohorts

Expanded Access Program (n = 19 evaluable patients; 6 pediatric, 13 adult):

  • CR rate: 68%
  • 100-day survival rate: 74%

SAFETY AND MONITORING
Key adverse reactions:

  • Serious infections — most clinically significant risk, consistent with the immunocompromised transplant population
  • Monitoring parameters: CBC, LDH, RFT

Notable: The FDA did not mandate a Boxed Warning or REMS for Yartemlea.

Full prescribing information should be reviewed prior to clinical use.

WHY THIS APPROVAL MATTERS

This approval represents a paradigm shift in TA-TMA management.

For decades, clinicians relied solely on:

  • Calcineurin inhibitor dose reduction (first-line supportive measure)
  • Plasma exchange (limited evidence, no approval)
  • Defibrotide (off-label use, no formal TA-TMA indication)

REFERENCES
1. U.S. Food and Drug Administration. FDA approves narsoplimab-wuug (Yartemlea) for hematopoietic stem cell transplant-associated thrombotic microangiopathy. December 24, 2025.
2. Omeros Corporation.”

Dhinesh Selvaraju: FDA Approves Narsoplimab (Yartemlea) as 1st Treatment for TA-TMA in Adults and Children

Stay updated with Hemostasis Today.

Defibrotide Dhinesh Selvaraju FDA Health Hematology Hemostasis Hemostasis News Hemostasis Today HSCT Medicine narsoplimab-wuug thrombosis thrombotic microangiopathy TMA Yartemlea
NewsFeed